Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Castrate-Resistant Prostate Cancer”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Not applicableApproved For MarketingNCT01606982
What this trial is testing

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Global Development, Inc.
Post-approval studies (Phase 4)Study completedNCT03641560
What this trial is testing

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Astellas Pharma Inc 52
Testing effectiveness (Phase 2)UnknownNCT01296243
What this trial is testing

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Genta Incorporated 57
Testing effectiveness (Phase 2)Study completedNCT03042468
What this trial is testing

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 50
Testing effectiveness (Phase 2)UnknownNCT04033432
What this trial is testing

SEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents+7 more
Northwestern University 14
Large-scale testing (Phase 3)WithdrawnNCT02053311
What this trial is testing

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Who this might be right for
Prostate Cancer
Swiss Cancer Institute
Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Testing effectiveness (Phase 2)Ended earlyNCT02933801
What this trial is testing

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Who this might be right for
Prostate Cancer MetastaticProstate Cancer
Swiss Cancer Institute 92
Large-scale testing (Phase 3)Study completedNCT03511664
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Endocyte 861
Testing effectiveness (Phase 2)Study completedNCT00005848
What this trial is testing

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Fox Chase Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Ended earlyNCT01732549
What this trial is testing

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer
Ipsen 144
Early research (Phase 1)Study completedNCT02106507
What this trial is testing

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Not applicableStudy completedNCT06460454
What this trial is testing

PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing

Who this might be right for
Prostate Cancer
Central Hospital, Nancy, France 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT02881242
What this trial is testing

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
Jonsson Comprehensive Cancer Center 14
Not applicableLooking for participantsNCT07538843
What this trial is testing

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 800
Testing effectiveness (Phase 2)Looking for participantsNCT07206056
What this trial is testing

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals 188
Large-scale testing (Phase 3)Looking for participantsNCT07311694
What this trial is testing

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 370
Next Page